Canada Markets open in 9 hrs 2 mins

Intellipharmaceutics International Inc. (IPCIF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.08210.0000 (0.00%)
At close: 10:17AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.0821
Open0.0821
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0821 - 0.0821
52 Week Range0.0800 - 0.3000
Volume26
Avg. Volume3,295
Market Cap2.718M
Beta (5Y Monthly)1.13
PE Ratio (TTM)N/A
EPS (TTM)-0.1080
Earnings DateOct 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Intellipharmaceutics Announces Third Quarter 2022 Results

    - Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2022.

  • ACCESSWIRE

    Intellipharmaceutics Signs an Exclusive License & Supply Agreement with Taro Pharmaceuticals Inc. for Desvenlafaxine Extended-Release Tablets

    Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that it has entered into a license and supply agreement with Taro Pharmaceuticals Inc. ("Taro"), by which the Company has granted Taro an exclusive license to

  • ACCESSWIRE

    Intellipharmaceutics Announces Second Quarter 2022 Results

    Intellipharmaceutics International Inc. (OTCQB:IPCIF)(TSX:IPCI)("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2022. All dollar amounts referenced herein are in United States dollars unless otherwise noted.